Hallux: Funding, Investors & Team (Oct 2026)
Hallux is a privately held clinical-stage pharmaceutical company that develops a new topical dosage form and route of administration for treating onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of infection over a period of time. Results from pilot studies are encouraging and suggest that the subungual treatment procedure is safe and well-tolerated. The company’s technology delivers high concentrations of the gold standard antifungal terbinafine directly and selectively to the site of infection without introducing it systemically, where it can affect the liver and interact with other drugs that patients may be taking. It was founded in 2012 and is headquartered in Laguna Hills, California.
Hallux has raised $9.4M across 1 funding round on record, the most recent an undisclosed round of $9.4M announced in Apr 2022.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Hallux Company Profile and Key Stats
Latest funding round on record: Apr 2022.
Hallux Funding Rounds
Hallux Founders and Leadership Team
No contact details are on record for this team yet.
Hallux Funding Compared to Other Biotechnology Startups
Hallux's latest round of $9.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Hallux in Biotechnology and Laguna Hills
Companies Similar to Hallux
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Hallux Funding FAQs
What does Hallux do?
Hallux is a privately held clinical-stage pharmaceutical company that develops a new topical dosage form and route of administration for treating onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of infection over a period of time. Results from pilot studies are encouraging and suggest that the subungual treatment procedure is safe and well-tolerated. The company’s technology delivers high concentrations of the gold standard antifungal terbinafine directly and selectively to the site of infection without introducing it systemically, where it can affect the liver and interact with other drugs that patients may be taking. It was founded in 2012 and is headquartered in Laguna Hills, California.
How much funding has Hallux raised?
Hallux has raised $9.4M across 1 round on record. The most recent is an undisclosed round of $9.4M announced in Apr 2022.
When did Hallux last raise funding?
Hallux's most recent funding round on record is an undisclosed round of $9.4M, announced in Apr 2022.
Who is the CEO of Hallux?
Milan Panic is listed as CEO at Hallux.
Where is Hallux headquartered?
Hallux is based in Laguna Hills, California, United States.
How many employees does Hallux have?
Hallux is in the 11-50 employee band.
How does Hallux's funding compare to other Biotechnology startups?
Hallux's latest round of $9.4M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Hallux Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Hallux is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.